ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2024
0mins
Source: NASDAQ.COM
- Eli Lilly and Company Earnings: Eli Lilly posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. The stock jumped 6% in response to the earnings beat.
- Revenue and Sales Growth: Revenues rose 26% to $8.77 billion, driven by strong sales of drugs like Mounjaro, Zepbound, Verzenio, and Jardiance. Mounjaro's sales saw a significant increase.
- 2024 Outlook: Eli Lilly raised its revenue guidance for 2024 due to tremendous sales growth for Mounjaro and Zepbound. Adjusted earnings per share were also increased.
- ETFs Exposure to Eli Lilly: Investors can consider ETFs with exposure to Eli Lilly, such as iShares U.S. Pharmaceuticals ETF, Horizon Kinetics Medical ETF, iShares U.S. Healthcare ETF, Health Care Select Sector SPDR Fund, and VanEck Vectors Pharmaceutical ETF.
- Details of Specific ETFs: Each ETF offers different exposure to Eli Lilly, with varying assets under management, fees, and risk outlooks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 903.990
Low
950.00
Averages
1192
High
1500
Current: 903.990
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly to Announce Q1 2026 Financial Results
- Earnings Announcement Date: Eli Lilly is set to release its Q1 2026 financial results on April 30, 2026, reflecting the company's ongoing commitment to transparency and investor communication.
- Conference Call Details: On the same day, Lilly will conduct a conference call at 10 a.m. Eastern Time to provide detailed insights into its financial performance, aimed at bolstering market confidence.
- Live Webcast Availability: Investors, media, and the general public can access a live webcast of the conference call through a link on Lilly's website, ensuring broad dissemination of information and transparency.
- Replay Feature: Following the call, a replay will be available on the website, further enhancing accessibility to information and aiding investors in understanding the company's financial status.
See More
Positive Phase 3 Results for Foundayo in Diabetes Treatment
- Cardiovascular Event Risk Reduction: In a study involving over 2,700 adults with type 2 diabetes, patients taking Foundayo experienced a 16% lower risk of major adverse cardiovascular events compared to those on insulin glargine, indicating Foundayo's significant advantage in cardiovascular safety, which may attract more patients to choose this medication.
- Significant Mortality Risk Reduction: A pre-planned analysis revealed that patients on Foundayo had a 57% lower risk of death from any cause compared to those on insulin glargine, further enhancing Foundayo's appeal as a diabetes treatment and potentially increasing its market acceptance.
- FDA Submission Plans: Based on the trial results, Eli Lilly plans to submit an application for Foundayo's approval to the FDA by the end of Q2, which, if approved, could open new market opportunities for the company in diabetes treatment and strengthen its product portfolio.
- Market Competition Dynamics: Despite the positive clinical results for Foundayo, retail investor sentiment towards Eli Lilly remains bearish, likely due to intense competition in the weight-loss drug market, particularly from Novo Nordisk, which may affect investor confidence in the company's future performance.
See More
Eli Lilly's Tirzepatide Shows Superior Weight Loss Effects Compared to Semaglutide
- Efficacy Comparison: A new study indicates that Eli Lilly's obesity therapy tirzepatide leads to greater weight loss compared to Novo Nordisk's semaglutide, showing LBM losses of 1.1%, 1.5%, 1.3%, and 2.0% greater at 3, 6, 9, and 12 months respectively, highlighting tirzepatide's significant advantage in weight reduction.
- Patient Data Analysis: The study analyzed data from 1,800 patients on tirzepatide and 6,200 on semaglutide, revealing that tirzepatide not only resulted in greater total body weight loss but also reinforced its competitive position in the market for GLP-1 drugs.
- Market Impact: Findings suggest that patients should not simply focus on the amount of weight loss when choosing weight loss medications, but also consider the impact on body composition, which could influence future prescription trends, especially following the launch of Eli Lilly's Zepbound and Mounjaro.
- Industry Competition: As Eli Lilly's tirzepatide demonstrates increasing advantages in the weight loss sector, Novo Nordisk's semaglutide faces intensified market competition, potentially prompting adjustments in product development and market strategies.
See More
Novo Nordisk and Eli Lilly Prescription Comparison
- Prescription Comparison: Novo Nordisk's oral obesity drug Wegovy received 3,071 prescriptions in its first four days post-launch in the U.S., while Eli Lilly's Foundayo garnered 1,390 prescriptions in its debut week, indicating a strong market presence for Novo Nordisk despite Lilly's promising start.
- Cardiovascular Risk Reduction: Eli Lilly's ACHIEVE-4 trial revealed that patients taking Foundayo had a 16% lower risk of major adverse cardiovascular events compared to those on insulin glargine, providing robust support for the drug's safety profile and potentially boosting market confidence.
- Usage Restrictions: Wegovy must be taken on an empty stomach with a 30-minute fasting period, whereas Foundayo can be consumed without food restrictions, which may enhance its appeal among patients and impact market share dynamics.
- Market Sentiment Shift: Retail sentiment on Stocktwits regarding Eli Lilly shifted from 'bearish' to 'neutral', with message volumes increasing from 'low' to 'normal', reflecting growing confidence in Lilly's obesity treatments and potentially driving its stock price upward.
See More
Eli Lilly's Weight-Loss Drug Off to Slow Start in U.S. Market
- Low Prescription Numbers: Eli Lilly's newly launched weight-loss drug garnered only about 1,390 prescriptions in its first week on the U.S. market, indicating both demand and significant challenges in promotion and market acceptance.
- Competitor's Clear Advantage: Novo Nordisk's competing therapy received over 113,000 prescriptions during the same period, highlighting its strong reputation among doctors and patients, putting Eli Lilly under considerable competitive pressure.
- Market Entry Timing: Lilly received U.S. government approval to sell the drug on April 1 and quickly launched it through a direct-to-consumer platform to accelerate market penetration, but initial performance requires time to validate.
- Long-Term Market Potential: Despite the disappointing initial prescription numbers, the weight-loss drug market remains a focal point in the pharmaceutical industry, and Lilly's promotional strategy may be a lengthy process, with prescription growth in the coming months being crucial.
See More
Eli Lilly's Foundayo Prescriptions Surge Post Launch
- Prescription Surge: Eli Lilly's new weight loss pill, Foundayo, saw prescriptions reach 1,390 for the week ending April 10, indicating a strong market response since its launch earlier this month, reflecting consumer acceptance of the new therapy.
- Competitor Performance: In contrast, Novo Nordisk's Wegovy approached 113,354 prescriptions during the same week, up from 105,366 the previous week, highlighting the sustained demand for GLP-1 drugs and intensifying competition in the market.
- FDA Approval Impact: Foundayo received FDA approval on April 1 as a once-daily treatment for obese or overweight adults, quickly accepting prescriptions through LillyDirect, showcasing the company's rapid market response capabilities.
- Market Outlook: With the launch of Foundayo, Eli Lilly significantly enhances its competitive position in the GLP-1 market, expected to challenge Novo Nordisk's market share and drive further growth in the overall weight loss drug market.
See More
Eli Lilly to Announce Q1 2026 Financial Results
- Earnings Announcement Date: Eli Lilly is set to release its Q1 2026 financial results on April 30, 2026, reflecting the company's ongoing commitment to transparency and investor communication.
- Conference Call Details: On the same day, Lilly will conduct a conference call at 10 a.m. Eastern Time to provide detailed insights into its financial performance, aimed at bolstering market confidence.
- Live Webcast Availability: Investors, media, and the general public can access a live webcast of the conference call through a link on Lilly's website, ensuring broad dissemination of information and transparency.
- Replay Feature: Following the call, a replay will be available on the website, further enhancing accessibility to information and aiding investors in understanding the company's financial status.
See More
Positive Phase 3 Results for Foundayo in Diabetes Treatment
- Cardiovascular Event Risk Reduction: In a study involving over 2,700 adults with type 2 diabetes, patients taking Foundayo experienced a 16% lower risk of major adverse cardiovascular events compared to those on insulin glargine, indicating Foundayo's significant advantage in cardiovascular safety, which may attract more patients to choose this medication.
- Significant Mortality Risk Reduction: A pre-planned analysis revealed that patients on Foundayo had a 57% lower risk of death from any cause compared to those on insulin glargine, further enhancing Foundayo's appeal as a diabetes treatment and potentially increasing its market acceptance.
- FDA Submission Plans: Based on the trial results, Eli Lilly plans to submit an application for Foundayo's approval to the FDA by the end of Q2, which, if approved, could open new market opportunities for the company in diabetes treatment and strengthen its product portfolio.
- Market Competition Dynamics: Despite the positive clinical results for Foundayo, retail investor sentiment towards Eli Lilly remains bearish, likely due to intense competition in the weight-loss drug market, particularly from Novo Nordisk, which may affect investor confidence in the company's future performance.
See More
Eli Lilly's Tirzepatide Shows Superior Weight Loss Effects Compared to Semaglutide
- Efficacy Comparison: A new study indicates that Eli Lilly's obesity therapy tirzepatide leads to greater weight loss compared to Novo Nordisk's semaglutide, showing LBM losses of 1.1%, 1.5%, 1.3%, and 2.0% greater at 3, 6, 9, and 12 months respectively, highlighting tirzepatide's significant advantage in weight reduction.
- Patient Data Analysis: The study analyzed data from 1,800 patients on tirzepatide and 6,200 on semaglutide, revealing that tirzepatide not only resulted in greater total body weight loss but also reinforced its competitive position in the market for GLP-1 drugs.
- Market Impact: Findings suggest that patients should not simply focus on the amount of weight loss when choosing weight loss medications, but also consider the impact on body composition, which could influence future prescription trends, especially following the launch of Eli Lilly's Zepbound and Mounjaro.
- Industry Competition: As Eli Lilly's tirzepatide demonstrates increasing advantages in the weight loss sector, Novo Nordisk's semaglutide faces intensified market competition, potentially prompting adjustments in product development and market strategies.
See More
Novo Nordisk and Eli Lilly Prescription Comparison
- Prescription Comparison: Novo Nordisk's oral obesity drug Wegovy received 3,071 prescriptions in its first four days post-launch in the U.S., while Eli Lilly's Foundayo garnered 1,390 prescriptions in its debut week, indicating a strong market presence for Novo Nordisk despite Lilly's promising start.
- Cardiovascular Risk Reduction: Eli Lilly's ACHIEVE-4 trial revealed that patients taking Foundayo had a 16% lower risk of major adverse cardiovascular events compared to those on insulin glargine, providing robust support for the drug's safety profile and potentially boosting market confidence.
- Usage Restrictions: Wegovy must be taken on an empty stomach with a 30-minute fasting period, whereas Foundayo can be consumed without food restrictions, which may enhance its appeal among patients and impact market share dynamics.
- Market Sentiment Shift: Retail sentiment on Stocktwits regarding Eli Lilly shifted from 'bearish' to 'neutral', with message volumes increasing from 'low' to 'normal', reflecting growing confidence in Lilly's obesity treatments and potentially driving its stock price upward.
See More
Eli Lilly's Weight-Loss Drug Off to Slow Start in U.S. Market
- Low Prescription Numbers: Eli Lilly's newly launched weight-loss drug garnered only about 1,390 prescriptions in its first week on the U.S. market, indicating both demand and significant challenges in promotion and market acceptance.
- Competitor's Clear Advantage: Novo Nordisk's competing therapy received over 113,000 prescriptions during the same period, highlighting its strong reputation among doctors and patients, putting Eli Lilly under considerable competitive pressure.
- Market Entry Timing: Lilly received U.S. government approval to sell the drug on April 1 and quickly launched it through a direct-to-consumer platform to accelerate market penetration, but initial performance requires time to validate.
- Long-Term Market Potential: Despite the disappointing initial prescription numbers, the weight-loss drug market remains a focal point in the pharmaceutical industry, and Lilly's promotional strategy may be a lengthy process, with prescription growth in the coming months being crucial.
See More
Eli Lilly's Foundayo Prescriptions Surge Post Launch
- Prescription Surge: Eli Lilly's new weight loss pill, Foundayo, saw prescriptions reach 1,390 for the week ending April 10, indicating a strong market response since its launch earlier this month, reflecting consumer acceptance of the new therapy.
- Competitor Performance: In contrast, Novo Nordisk's Wegovy approached 113,354 prescriptions during the same week, up from 105,366 the previous week, highlighting the sustained demand for GLP-1 drugs and intensifying competition in the market.
- FDA Approval Impact: Foundayo received FDA approval on April 1 as a once-daily treatment for obese or overweight adults, quickly accepting prescriptions through LillyDirect, showcasing the company's rapid market response capabilities.
- Market Outlook: With the launch of Foundayo, Eli Lilly significantly enhances its competitive position in the GLP-1 market, expected to challenge Novo Nordisk's market share and drive further growth in the overall weight loss drug market.
See More
